Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $68.30 USD
Change Today -0.59 / -0.86%
Volume 4.4M
BMY On Other Exchanges
New York
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/20/15 - $69.86
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Executive Chairman, Officer, Ex-Officio Membe...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients. The updated Designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those who develop genotype 1 HCV recurrence post-liver transplant. Breakthrough Therapy Designation requires preliminary clinical evidence that demonstrates a drug may have substantial improvement on at least one clinically significant endpoint over available therapy. The designation is supported by data from ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with HCV with either advanced cirrhosis or post-liver transplant recurrence of HCV. Results from ALLY-1 were recently presented at The International Liver Congress 2015, this year’s annual meeting of the European Association for the Study of the Liver. According to the FDA, Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The FDA first granted a Designation for the daclatasvir and sofosbuvir combination in 2013; since that time, there have been significant developments in the field of HCV. That has led the FDA to review, modify, and in some cases, rescind previously granted HCV-related Designations.

Bristol-Myers Squibb Company Announces the Pricing Terms of its Cash Tender Offer for Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities

Bristol-Myers Squibb Company announced the pricing terms of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of its outstanding debt securities. The total consideration for each series of notes includes an early tender premium of $30 per $1,000 principal amount of notes validly tendered and not validly withdrawn by such holders and accepted for purchase by Bristol-Myers Squibb. All payments for notes purchased in connection with the early tender date will also include accrued and unpaid interest on the principal amount of notes tendered up to, but not including, the initial settlement date, which is currently expected to be May 13, 2015. Bristol-Myers Squibb expects it will accept for purchase notes validly tendered and not validly withdrawn prior to the early tender date in an aggregate principal amount up to the tender cap. Tendered notes are expected to be accepted in the order of the acceptance priority levels. Bristol-Myers Squibb has previously announced the anticipated principal amount it expects to accept of each series of notes. The tender offer is scheduled to expire on May 26, 2015, unless extended or earlier terminated.

Bristol-Myers Squibb Company Approves Amended and Restated Certificate of Incorporation

Bristol-Myers Squibb Company approved the proposal to amend the company’s amended and restated certificate of incorporation to remove the supermajority provisions applicable to preferred stockholders, at the annual meeting held on May 5, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $68.30 USD -0.59

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $65.48 USD -0.17
Actavis plc $301.35 USD +0.13
Amgen Inc $163.58 USD -0.26
Medtronic PLC $77.82 USD -0.59
Novo Nordisk A/S kr390.30 DKK +2.30
View Industry Companies

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 50.7x
Price/Sales 7.1x
Price/Book 7.3x
Price/Cash Flow 50.5x
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at